# Michael J. Birrer

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-j-birrer/

## Facts

| Field | Value |
| --- | --- |
| Citations | 90,601 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 125 |
| i10-index | 402 |
| Last Known Institution | University of Arkansas Medical Center |
| OpenAlex ID | https://openalex.org/A5103220093 |
| ORCID iD | https://orcid.org/0000-0002-3861-4521 |
| Works | 1,068 |

## Researcher papers

- [Pan-cancer analysis of whole genomes](https://scholariq.org/papers/pan-cancer-analysis-of-whole-genomes/)
- [Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer](https://scholariq.org/papers/incorporation-of-bevacizumab-in-the-primary-treatment-of-ovarian-cancer/)
- [Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis](https://scholariq.org/papers/requirement-for-ceramide-initiated-sapk-jnk-signalling-in-stress-induced/)
- [Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)](https://scholariq.org/papers/bevacizumab-for-advanced-cervical-cancer-final-overall-survival-and-adverse/)
- [Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer](https://scholariq.org/papers/identification-of-12-new-susceptibility-loci-for-different-histotypes-of/)
- [Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer](https://scholariq.org/papers/final-overall-survival-of-a-randomized-trial-of-bevacizumab-for-primary/)
- [Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer](https://scholariq.org/papers/weekly-vs-every-3-week-paclitaxel-and-carboplatin-for-ovarian-cancer/)
- [A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24](https://scholariq.org/papers/a-genome-wide-association-study-identifies-susceptibility-loci-for-ovarian/)
- [Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial](https://scholariq.org/papers/olaparib-and-specific-pi3k-inhibitor-alpelisib-for-patients-with-epithelial/)
- [Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study](https://scholariq.org/papers/safety-and-activity-of-mirvetuximab-soravtansine-imgn853-a-folate-receptor-alpha/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer-related molecular mechanisms research](https://scholariq.org/topics/cancer-related-molecular-mechanisms-research/)

## Researcher university

- [University of Arkansas Medical Center](https://scholariq.org/institutions/university-of-arkansas-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.